John Vandermosten

YouTube video by Unboxing Biotech Mpox Vaccine Details

GeoVax press release today calling to sustain effort against Mpox emphasized by WHO Head Rosamund Lewis, MD.
geovax.com/investors/pr...
See our talk with $GOVX CEO David Dodd on the subject:
youtu.be/4gh9M-_CEuc

YouTube video by Unboxing Biotech Anti VISTA to Unshackle T Cells

Tuhura's Dr Bianco provides background on TBS-2025 in our recent conversation tying into today's announcement:
youtu.be/rLgaMjuZyNI

Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules KANSAS CITY, Kan., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced t...

Cingulate closes $12mm private placement to support commercial launch of CTx-1301
*PIPE with Falcon Creek who will have 2 board seats
*$5.04/share & 80% warrants
*180 day lock up
$CING
finance.yahoo.com/news/cingula...

TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that...

TuHURA files IND for TBS-2025 (anti-VISTA) with FDA for treatment of blood-related cancers
*With a menin inhibitor
*In NPM1 mutated patients
*relapsed/refractory AML
*Upon clearance will launch Ph2 expected 2Q26
$HURA
finance.yahoo.com/news/tuhura-...

Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin JUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing p...

Dyadic launches albuminwith Proliant Health & Biologicals
*AlbuFree DX
*$DYAI to receive share of profits
finance.yahoo.com/news/dyadic-...

YouTube video by Unboxing Biotech Sales Strategy

EVP and Chief Commercial Officer Bryan Downey describes Cingulate’s sales and marketing strategy for CTx-1301. $CING #CTx-1301 #ADHD #PrecisionTimedRelease #PTR #NASDAQ #Biotech #BioPharma #FDA #FDAApproval #PDUFA #NDA #DrugDelivery #ExtendedRelease #ControlledRelease
youtube.com/shorts/sVbvZ...

YouTube video by Unboxing Biotech Merkel Cell Carcinoma Trial Differences

TuHURA is running two clinical trials for IFx-2.0 in Merkel cell carcinoma. One is a Phase III and the other is a Phase II. Dr Bianco explains the difference.
$HURA #ImmunoOncology #CancerResearch #LifeSciences
youtu.be/iK0wkXlwLoQ

YouTube video by Unboxing Biotech Payors and CTx1301

Cingulate’s SVP of Market Access Rick Arce makes the case for CTx-1301 to payors we move towards the May 31 2026 target action date.
$CING
#PrecisionTimedRelease #PTR #NASDAQ #Biotech #BioPharma #FDA #FDAApproval #PDUFA #NDA #DrugDelivery
youtube.com/shorts/aKWRi...

YouTube video by Unboxing Biotech TuHURA's ADC Options

TuHURA to present at Oppenheimer Life Sciences Conference 26Feb finance.yahoo.com/news/tuhura-...
$HURA
To prepare, check out our talk w/ CEO Dr Bianco on ADCs
youtu.be/brUktlLlD74

Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 JUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday,...

Ligand Pharmaceuticals to report 4Q25 on 26Feb26
*8:30 am ET
*Webcast details in PR
$LGND
finance.yahoo.com/news/ligand-...

YouTube video by Unboxing Biotech Patient Demographics and Insights

EVP & Chief Commercial Officer Bryan Downey explains Cingulate’s commercialization efforts and how young adult women fit in as patients, caregivers & decision makers for family health care.
$CING
CTx-1301 #ADHD #PTR #NASDAQ #Biotech #BioPharma #FDA #PDUFA #NDA
youtube.com/shorts/UVKJ3...

YouTube video by Unboxing Biotech Tuning the Immune System

TuHURA CEO Dr Bianco explains how interacting with the Delta Opioid Receptor (DOR) can tune the immune system to find the balance between the extremes of immune deficiency (allowing cancer and pathogens to survive) to an overactive immune system (autoimmune disease)
$HURA
youtu.be/jKOIDNJ0ceY

Spectral AI Names Vincent S. Capone as Chief Executive Officer DALLAS, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more ...

Spectral AI appoints Vincent Capone as CEO, effective 9Feb.
Alters the previous Office of the Chairman structure as we look towards the FDA decision on DeepView approval mid year 2026.
$MDAI
finance.yahoo.com/news/spectra...

YouTube video by Unboxing Biotech Indigene's Commercialization Role

EVP and Chief Commercial Officer Bryan Downey explains Indegene’s role in Cingulate’s commercialization efforts for CTx-1301 in ADHD. $CING
#PrecisionTimedRelease #PTR #NASDAQ #Biotech #BioPharma #FDA #FDAApproval #PDUFA #NDA #ControlledRelease #Dexmethylphenidate
youtube.com/shorts/UnnYM...

Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced its Special Meeting scheduled for a...

Azitra adjourns shareholders' meeting until March 6th giving time to gather a quorum. Vote your shares $AZTR stockholders!
finance.yahoo.com/news/azitra-...

YouTube video by Unboxing Biotech DOR Inhibition & the Tumor Microenvironment

TuHURA Biosciences CEO Dr. James Bianco explains the mechanism of action for the Delta Opioid Receptor which modifies the tumor microenvironment rather than targeting the tumor itself.
$HURA
#ImmunoOncology #CancerResearch #CancerImmunotherapy #ImmuneSuppression #MDSCs
youtu.be/8xSUa9LjsNk

YouTube video by Unboxing Biotech Market Access and Strategy

As we advance to CTx-1301’s 31May26 target action date, Cingulate SVP of Market Access Rick Arce explains the process of getting payors on board. $CING
#PrecisionTimedRelease #PTR #NASDAQ #Biotech #BioPharma #FDA #FDAApproval #PDUFA #NDA #DrugDelivery #Dexmethylphenidate
youtube.com/shorts/T-fYV...

YouTube video by Unboxing Biotech DOR Oral Presentation at ASH

TuHURA Biosciences presented its Delta Opioid Receptor findings at the American Society of Hematology (ASH) annual meeting in December 2025. CEO Dr James Bianco explains.
youtu.be/wPTPhbdw43Q

YouTube video by Unboxing Biotech Benefits of Cingulate CTx 1301

As we move towards CTx-1301’s 31May26 target action date, Cingulate CEO Shane Schaffer describes payors reactions to the medicine. $CING
#PrecisionTimedRelease #PTR #NASDAQ #Biotech #BioPharma #FDA #PDUFA #NDAFails
youtube.com/shorts/nIzin...

Lexaria Bioscience announces final results from pilot study #5
*DehydraTECH liraglutide vs Saxenda
~DHT arm had fewer adverse events
~seeking path to oral formulation of DHT-liraglutide
$LEXX PR summarizes study details
lexariabioscience.com/2026/02/05/l...

Join Dr Bianco as he describes TuHURA Biosciences' IFx-2.0 program in Merkel cell carcinoma.
$HURA
youtu.be/TQpM99rULTI

TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma TAMPA, Fla., Feb. 2, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology…...

TuHURA Biosciences receives Orphan Drug Designation for IFx-2.0 for Stage IIB to Stage IV cutaneous melanoma.
$HURA
ir.tuhurabio.com/news-events/...

actually, here is the link to where we discuss the CHMP opinion:
s27.q4cdn.com/906368049/fi...

Protalix receives positive opinion on 4 week dosing of Elfabrio in Europe vs the 2 now approved in Fabry disease.
Follows re-examination request.
If EC approves, $PLX eligible for $25mm milestone.
We discuss here: s27.q4cdn.com/906368049/fi...
PR: ir.protalix.com/news-release...

Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases Interim data...

Radiopharm Theranostics reports 1H26 results & provides pipeline update.
$RADX
finance.yahoo.com/news/radioph...

Cardiff Oncology CEO & CFO step down. Board member Dr Mohindru interim CEO.
Also announces onvansertib Ph2 update
*30mg pivotal dose
*final data in 1H26
*Call @ 8:30 am ET
$CRDF
investors.cardiffoncology.com/news-release...

YouTube video by Unboxing Biotech Zacks SCR 2026 Picks

Zacks SCR highlights its best picks for 2026. See our clip below for our thoughts on $TRX $SBC $CBAT $TNXP $DYLLF $HITI $BGL $RADX
youtu.be/KCDybCJKrKk

Lexaria Awarded Six Additional Patents Lexaria now has 60 patents granted around much of the world Lexaria urges shareholders to vote at upcoming 2026 Annual Meeting KELOWNA, BC / ACCESS Newswire / January 22, 2026 / Lexaria Bioscience Cor...

Lexaria Bioscience awarded 6 new patents
*Brings total to 60
~sublingual nicotine delivery 🇦🇺
~hypertension 🇪🇺
~epilepsy 🇪🇺 🇦🇺 🇺🇸
~diabetes 🇺🇸
VOTE $LEXX SHARES 27JAN! (TOMORROW) @ annual meeting
finance.yahoo.com/news/lexaria...

YouTube video by Unboxing Biotech VISTA's Role in Leukemia

TuHURA Biosciences acquired an anti-VISTA asset from Kineta last year. CEO Dr. James Bianco explains the role of the checkpoint inhibitor in leukemias such as AML.
$HURA
#AML #VISTA #ImmunoOncology
youtube.com/shorts/r5D79...

YouTube video by Unboxing Biotech Gedeptin in New Solid Tumors

GeoVax is developing its Gedeptin Gene-Directed Enzyme Prodrug Therapy, which is a type of targeted chemotherapy & gene therapy, which it is using in combination with checkpoint inhibitors. CEO David Dodd looks @ solid tumors where Gedeptin has shown promise. #biotech
$GOVX
youtu.be/akLYO-8Tl0U